Hull Prospective Analysis of OnabotulinumtoxinA (Botox) in the treatment of Chronic Migraine; a real-life data in 972 patients; updated results on over 8 years of experience

被引：0
|
作者：
Ahmed, Fayyaz [1 ]
Buture, Alina [1 ]
Tanvir, Taukir [1 ]
Khalil, Modar [1 ]
机构：
[1] Hull York Med Sch, Neurosci, Kingston Upon Hull, N Humberside, England
来源：
CEPHALALGIA | 2019年 / 39卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
IHC-PO-423
引用
收藏
页码：276 / 277
页数：2
相关论文
共 50 条
  • [21] DOES MEDICATION OVERUSE MATTER? RESPONSE TO ONABOTULINUMTOXINA IN CHRONIC MIGRAINE (CM) PATIENTS WITH OR WITHOUT MEDICATION OVERUSE; UPDATE FROM REAL-LIFE DATA
    Ahmed, F.
    Khalil, M.
    Tanvir, T.
    Buture, A.
    CEPHALALGIA, 2018, 38 : 85 - 86
  • [22] Does Medication overuse matter? Response to OnabotulinumtoxinA in Chronic Migraine (CM) patients with or without medication overuse; update from real-life data
    Khalil, Modar
    Buture, Alina
    Ghabeli, Ali J.
    Ahmed, Fayyaz
    CEPHALALGIA, 2017, 37 : 112 - 113
  • [23] A single-center retrospective study of onabotulinumtoxinA for treatment of 245 chronic migraine patients: survey results of a real-world experience
    Pınar Yalinay Dikmen
    Seda Kosak
    Elif Ilgaz Aydinlar
    Ayse Sagduyu Kocaman
    Acta Neurologica Belgica, 2018, 118 : 475 - 484
  • [24] Quarterly repeat cycles of onabotulinumtoxinA in chronic migraine patients: the benefits of the prolonged treatment on the continuous responders and quality-of-life conversion rate in a real-life setting
    Santoro, Antonio
    Fontana, Andrea
    Miscio, Anna M.
    Zarrelli, Michele M.
    Copetti, Massimiliano
    Leone, Maurizio A.
    NEUROLOGICAL SCIENCES, 2017, 38 (10) : 1779 - 1789
  • [25] A single-center retrospective study of onabotulinumtoxinA for treatment of 245 chronic migraine patients: survey results of a real-world experience
    Dikmen, Pinar Yalinay
    Kosak, Seda
    Aydinlar, Elif Ilgaz
    Kocaman, Ayse Sagduyu
    ACTA NEUROLOGICA BELGICA, 2018, 118 (03) : 475 - 484
  • [26] Quarterly repeat cycles of onabotulinumtoxinA in chronic migraine patients: the benefits of the prolonged treatment on the continuous responders and quality-of-life conversion rate in a real-life setting
    Antonio Santoro
    Andrea Fontana
    Anna M. Miscio
    Michele M. Zarrelli
    Massimiliano Copetti
    Maurizio A. Leone
    Neurological Sciences, 2017, 38 : 1779 - 1789
  • [27] Stopping Onabotulinum treatment after the first 2 cycles might not be justified: results of a real-life monocentric prospective study in chronic migraine
    Romoli, Michele
    Corbelli, Ilenia
    Bernetti, Laura
    Verzina, Angela
    Brahimi, Elona
    Caproni, Stefano
    Eusebi, Paolo
    Costa, Cinzia
    Calabresi, Paolo
    Sarchielli, Paola
    JOURNAL OF HEADACHE AND PAIN, 2017, 18
  • [28] Stopping Onabotulinum Treatment after the First Two Cycles Might Not Be Justified: Results of a Real-life Monocentric Prospective Study in Chronic Migraine
    Sarchielli, Paola
    Romoli, Michele
    Corbelli, Ilenia
    Bernetti, Laura
    Verzina, Angela
    Brahimi, Elona
    Eusebi, Paolo
    Caproni, Stefano
    Calabresi, Paolo
    FRONTIERS IN NEUROLOGY, 2017, 8
  • [29] ANALYSIS OF SURVIVAL AND REAL-LIFE TREATMENT IN PATIENTS WITH CHRONIC LYMPHATIC LEUKEMIA BETWEEN THE YEARS 2012 AND 2019
    Carpizo, Jimenez N.
    Gomez-Cornejo, Diaz F.
    Andres, Hernandez N.
    Campano, Garcia A.
    Cantalapiedra, Diez A.
    Bonis, Izquierdo E.
    Cidoncha, Morcillo B.
    Silvestre, Cristobal L. A.
    Fernandez, Fernandez E.
    Gutierrez, Perez O.
    Fernandez, Fontecha E.
    Pozas, Manas M. A.
    Urrutia, Rodriguez S.
    Ortin, Miguel M.
    Garcia-Frade, Uria L. J.
    HAEMATOLOGICA, 2020, 105 : 232 - 232
  • [30] Omalizumab in the treatment of chronic spontaneous urticaria in pediatric patients from the age of 6 years (real-life experience of one center)
    Petrovicova, O.
    Banovcin, P.
    Malicherova, E. Jurkova
    Bobcakova, A.
    Jesenak, M.
    ALLERGY, 2023, 78
12345